<DOC>
	<DOCNO>NCT02182583</DOCNO>
	<brief_summary>The objective study investigate efficacy safety Ba253BINEB continuous 4 week administration patient COPD use Ba253MDI ( TersiganÂ® aerosol ) comparator drug .</brief_summary>
	<brief_title>Ba253BINEB Compared Ba253MDI ( Metered Dose Inhaler ) Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Oxitropium</mesh_term>
	<criteria>The patient COPD ( chronic bronchitis , emphysema ) satisfy follow criterion 1 . Patients whose symptom stable least 4 symptomatic day week 2 . Patients FEV1.0/FVC &lt; = 70 % screen test 3 . Patients age &gt; = 40 year old 4 . Patients must able inhale study drug via BINEB MDI 5 . Patients must able understand patient information form Those correspond follow shall exclude subject study . 1 . Patients complicate bronchial asthma , make assessment drug efficacy COPD difficult 2 . Patients constantly administer oral steroid 3 . Patients glaucoma 4 . Patients prostatic hypertrophy 5 . Patients hypersensitivity anticholinergic drug Beta2 agonist . 6 . Patients serious hepatic disease , kidney disease heart disorder judge investigator inappropriate subject study 7 . Women pregnant may become pregnant , nursing woman 8 . Patients judge investigator inappropriate subject study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>